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Introduction:Madras motor neuron disease (MMND), MMND variant (MMNDV) and Familial MMND (FMMND)
have a unique geographic distribution predominantly reported from Southern India. The characteristic features
are onset in young, weakness and wasting of limbs, multiple lower cranial nerve palsies and sensorineural
hearing loss. There is a considerable overlap in the phenotype of MMND with Brown–Vialetto–Van Laere
syndrome (BVVL) Boltshauser syndrome, Nathalie syndrome and Fazio–Londe syndrome. Recently a number
of BVVL cases and families have been described with mutations in two riboﬂavin transporter genes SLC52A2
and SLC52A3 (solute carrier family 52, riboﬂavin transporter, member 2 and 3 respectively).
Methods and results:We describe six families and four sporadicMMND cases that have been clinically character-
ized in detail with history, examination, imaging and electrophysiological investigations. We sequenced the
SLC52A1, SLC52A2 and SLC52A3 in affected probands and sporadic individuals from the MMND series as well
as the C9ORF72 expansion. No genetic defects were identiﬁed and the C9ORF72 repeats were all less than 10.
Conclusions: These data suggest that MMND is a distinct clinical subgroup of childhood onset MND patients
where the known genetic defects are so far negative. The clinico-genetic features of MMND in comparison
with the BVVL group of childhood motor neuron diseases suggest that these diseases are likely to share a
common defective biological pathway that may be a combination of genetic and environmental factors.© 2013 Published by Elsevier B.V.1. Introduction
Madras motor neuron disease (MMND) a unique disorder which
was described in 1970, was a name given by Meenakshisundaram
et al. to a group of patients from Madras (now called Chennai) located
in Southern India [1]. The disease manifests in young individuals with
clinical features of thin habitus, wasting and weakness predominantly
of distal muscles of the limbs, involvement of facial and bulbar muscles,
pyramidal dysfunction and associated sensorineural hearing impair-
ment. The disease was described as a sporadic disorder with benign
course [1,2]. Later they described the same disorder in additional 29
cases [2,3]. Subsequently a few more reports from Bangalore and Vel-
lore in the South,Mumbai in theWest and Kolkata in the Eastwere pub-
lished [4–10]. Apart from reports mainly from India three independent
cases, one each from Thailand, Italy and China have been reported and
curiously the patient in the Italian report had originated from South
India [11–13]. Although the earliest reports stated that it was aculty Block, National Institute of
e 560 029, India. Tel.: +91 80
nimhans.nic.in (A. Nalini).
vier B.V.sporadic benign disorder, we have reported on the familial form of
MMND and also observed that the disorders could have a more
rapid and fatal course [14]. We have reported on the entity of
MMND variant wherein these patients in addition have features of
optic atrophy [15].
MMND overlaps clinically with Brown–Vialetto–Van Laere Syn-
drome (BVVL) [16,17], which in itself is likely allelic to a number of
other complex childhood motor neuron diseases such as Boltshauser
syndrome [18], Nathalie syndrome [19] and Fazio–Londe syndrome
[20]. Recently, mutations in the gene SLC52A3 (solute carrier family
52, riboﬂavin transporter, member 3) were identiﬁed as a cause of
BVVL in a consanguineous family with multiple affected individuals
[21,22]. Mutations were subsequently found in 6 additional families.
In humans there are 3 members of the riboﬂavin transporter family,
SLC52A1, SLC52A2 and SLC52A3 [23,24]. SLC52A2 and SLC52A3
cause typical BVVL and SLC52A1 causes a complex childhood
syndrome with similar neurological features. The great importance
of identifying mutations in this patient group is that riboﬂavin
supplementation improves the clinical phenotype.
Here we describe the detailed clinical phenotype and genetic
screening of six MMND families and four sporadic cases. The SLC52A1,
SLC52A2 and SLC52A3 genes were sequenced and the series was
Table 2
Primers used in the analysis childhood motor neuron disorders.
C20orf54
C20orf54 Exon 2-1
Forward TCACAGGAAGGGGAGTAATAAG
Reverse CCAGCACCCAGGAGGTC
C20orf54 Exon 2-2
Forward TCCGAAGTGCCCATCATC
Reverse AGAAGGATGGAGGTGAGCAG
C20orf54 Exon 3-1
Forward GCAGTCATTATTGCCACCTTG
Reverse AGGCCACCAGGGTATAGAT
C20orf54 Exon 3-2
Forward ACCAGGTCACCCTCCACTC
Reverse TAGGTGCGTTTGGAATTCTG
C20orf54 Exon 4
Forward TATGGAGACACTGGCCATCC
Reverse CCCAAGCTCTCCCAGGC
C20orf54 Exon 5
Forward GCCCTGTGAGAGTTCTTTGC
Reverse GGCACTTGCGTTCATGATTC
GPR172A
GPR172A Exon 2
Forward CAGTTCCCCTGGTCTCACC
Reverse CACCCTCTGGAAGCTCTCTG
GPR172A Exon 3-1
Forward GCAGGTGTGCCCAAGACT
Reverse GAAAACGCTCAAGGAAGTCG
GPR172A Exon 3-2
Forward ATGCTGTGCCTCGAATGTC
Reverse GCTCTTGCAGTGGTGAGGAC
GPR172A Exon 3-3
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be a common cause of MND [25,26].
2. Materials and method
Ten patients with classical features of MMND were studied in this
report. All these patients had volunteered and gave written informed
consent to perform the genetic analysis for presence of BVVL gene in
their blood samples. All patients were evaluated at the National
Institute of Mental Health and Neurosciences, a tertiary national
referral center for neurological disorders. The medical records were
scrutinized and all data regarding the clinical features including
electromyography, nerve conduction studies, audiological investiga-
tions, visual evoked potentials, CT scan and MRI brain ﬁndings were
entered into a proforma. After the consent 10 ml of blood for genomic
DNA was collected and DNA separated and stored at the Molecular
genetics laboratory DNA Bank at the Institute. Patients were informed
about the non-availability of facilities in India to genetically diagnose
these rare orphan disorders and hence they opted to have the genetic
testing for MMND and BVVL syndrome in the UK and the DNA samples
were transferred by the patients.
2.1. Sanger sequencing
SLC52A1, SLC52A2 and SLC52A3 PCR primers were designed using
Exon Primer so that PCR products would span whole exons andTable 1
Clinical features of 10 patients with MMND. Where percentage is not applicable the
expression is indicated beside the variable. SD = standard deviation, symm =symmetrical,
asymm = asymmetrical, dis = distal, prox = proximal, UL = upper limbs, bil = bilateral.
Clinical characteristics Total (n = 10)
Number of patients Percentage
Age at presentation (mean ± SD) years (range) 21.8 ± 6.54(11–31)
Age at onset (mean ± SD) years (range) 14.8 ± 4.34(9–20)
Duration of illness (mean ± SD) months
(range)
85.0 ± 54.7 (3–168)
Symptom at onset
Hearing impairment 6 60.0
UL wasting/weakness 2 20.0
Reduced vision 1 10.0
Hearing + vision 1 10.0
Neurological deﬁcits
Bilateral optic atrophy 6 60.0
Bilateral visual impairment 4 40.0
Bifacial weakness 5 50.0
Sensorineural deafness 10 100.0
IX to XII cranial nerves 10 100.0
Severe hypophonia 9 90.0
Atrophy and weakness
Upper limbs 7 70.0
Symmetrical/asymmetrical 5/2
Distribution
Distal 7 100.0
Prox 3 42.8
Lower limbs 3 30.0
Symm/asymm 2/1
Distribution
Distal 3 100.0
Prox 0
Deep tendon reﬂexes
Upper limbs
Normal 2 20.0
Sluggish/absent 2 20.0
Brisk 2 20.0
Exaggerated 4 40.0
Lower limbs
Brisk 1 10.0
Exaggerated 9 90.0
Babinski sign 5 50.0
Cerebellar signs 3 30.0
Forward CCACCACCATCTGTACCCAC
Reverse GAGCGAGCAGAATGTCAGG
GPR172A Exon 4
Forward GCTTTTCCTGCTTACCCTACG
Reverse GAGAACACGCCAAGACACAG
GPR172A Exon 5
Forward GTGGTCCTCGTGGTGAGC
Reverse CAGGCACTCAGGCATGG
GPR172B
GPR172B Primer pair 1
Forward AGCATCTTTGGACCTACC
Reverse TAGGAAGGCCACAGAGTG
GPR172B Primer pair 2
Forward GCCTGTGGTGGTAAAAGACC
Reverse TAGGGCACTGAGACCCTGAC
GPR172B Primer pair 3
Forward CTGAGTGTAGTGGGCACAG
Reverse ACCATGGGCTGAGAACAG
GPR172B Primer pair 4
Forward AGGAAGAAGAGGCTTTGC
Reverse ACACAGACACAGCACCCAC
GPR172B Primer pair 5
Forward GAGCAAGTGGAGACATGAAG
Reverse AGCCTCACGATGAAGACAGapproximately 35 bp of ﬂanking introns (http://ihg.gsf.de/ihg/
ExonPrimer.html) (Table 2). PCR primers were also designed for
SLC52A1 and SLC52A3 as above and previously described [27,28]. PCR
ampliﬁcation was performed using 25 ng of genomic DNA, 12 μl 2×
PCR Master Mix (Roche, Indianapolis, IN), 1 μl each of 10 μM forward
and reverse primers, and 2 μl H2O. Touchdown PCR was performed as
follows: 95 °C for 5 min, followed by 8 cycles of denaturing at 95 °C
for 20 s, annealing at 60 °C for 20 s, and extending at 72 °C for 30 s.
Following these 8 cycles, 20 cycles of the same conditions were run,
however the annealing temperature was decreased by 0.5 °C per cycle
until the ﬁnal annealing temperature reached 50 °C. Finally, 12 cycles
were run with denaturing at 95 °C for 20 s, annealing at 50 °C for
20 s, and extending at 72 °C for 30 s. Product underwentﬁnal extension
at 72 °C for 5 min. PCR ampliﬁcation products were cleaned with
AMPure SPRI beads as per the manufacturer's protocol (Agencourt,
Danvers, MA, US).
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template per each sequencing reaction. Sequencing reactions contained
5× reaction buffer (2 μl), big dye (0.5 μl) (Applied Biosystems, Foster
City, CA) and H2O (5.5 μl), and the forward or reverse primer that was
used for ampliﬁcation of the original product (1 μl). Conditions were
as follows: 25 cycles of denaturation at 95 °C, annealing at 50 °C, and
extension at 60 °C were performed. Sequencing reactions were cleaned
using CleanSEQ SPRI beads as per the manufacturer's protocol
(Agencourt). Sequencing was performed using the 3730 DNA Analyzer
(Applied Biosystems).
We screened the GGGGCC expansion in the MMND cohort and
the controls using the reversed-prime PCR protocol as previously
reported. Brieﬂy, 100 ng of genomic DNA was ampliﬁed with a
ﬁnal volume of 20 μl containing 10 μl FastStart PCR Master Mix
(Roche), 0.18 mM 7-deaza dGTP, 1× Qiagen Q solution, 10% DMSO,
0.7 μM reverse primer consisting of four GGGGCC repeats and an
anchor tail (TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCC
GGGG), 1.4 μM 6FAM ﬂuorescent-primer located 280 bp 3′ prime
to the repeat sequence (AGTCGCTAGAGGCGAAAGC) and 1.4 μM an-
chor primer corresponding to the anchor tail of the reverse primer
(TACGCATCCCAGTTTGAGACG). A touchdown PCR cycling protocol
was used where the initial annealing temperature was lowered
from 70 °C to 56 °C in 2 °C increments and a 3 min extension time
for each cycle. Fragment length analysis was performed on an ABI
3730XL genetic analyzer (Applied Biosystems Inc., Foster City, CA,
USA), and data analyzed using ABI GeneScan software. Each case
was analyzed in duplicate to conﬁrm allele sizes.
3. Audiological assessment
Hearing acuity was established at octave frequencies from 250 Hz to
8000 Hz for air conduction and 250 Hz to 4000 Hz for bone conduction.
Degree of hearing impairment was classiﬁed based on the average of air
conduction pure tone thresholds at all octave frequencies tested hereafter
referred to as all frequency average (AFA). This method of averaging was
for a relatively better reﬂection of average hearing level. Based on AFA,
the patients were grouped as per the three frequency average classiﬁca-
tion [29] as normal hearing (−10 to 25 dB), mild (26–40 dB), moderate
(41–55 dB), moderately severe (56–70 dB), severe (71–90 dB) and
profound (N90 dB) hearing loss. Pure tone audiometric ﬁndings were
analyzed in terms of percentage of ears affected.
4. Statistical analysis
Descriptive statisticsmean ± standard deviation (range) for contin-
uous variables and number (percentage) for categorical variables were
used to express data. All the data analyses were carried out using SPSS
Ver. 13.0.
5. Results
Nine of the ten patients hailed fromSouthern India. Therewere seven
males. The diagnosis was FamilialMMND in 6 patients [FMMD variant-5,
FMMND-1], Sporadic MMND in 4 cases [SMMND variant-2, SMMND-2].
Mean age at onset was 14.8 ± 4.34 years (range, 9–20). Mean age at
presentation was 21.8 ± 6.5 years (range, 11–31). Mean duration of
illness was 85.0 ± 54.7 months (3–168). Classically majority had a
slender habitus. The salient neurological symptoms and signs among
these 10 patients are shown in Table 1. The predominant initial symptom
at onset was impaired hearing in 6 patients (60.0%). The neurological
deﬁcits were bilateral optic atrophy in 6 patients (60.0%) and associated
mild visual impairment in 4 patients (66.6%). Bifacial weakness was
noted in 5 patients (50.0%). Clinical hearing impairment in 10 patients
(100.0%). Bulbar weakness in 10 patients (100.0%) [dysarthria in all 9
patients (90.0%), hypophonia in 9 patients (90.0%)]. Moderate to severe
atrophy of the tongue with fasciculations was seen in 8 patients (80.0%).Wasting and weakness of distal muscles of the upper limbs were
observed in 7 patients (70.0%). Wasting and weakness of distal muscles
of the lower limbs were present in 3 patients (30.0%). Small muscles of
the hand were severely weak when the upper limbs were affected.
Signs of pyramidal tract dysfunction in the upper limbs were seen in 6
patients (60.0%), and in the lower limbs in 10 patients (100.0%).
Babinski's sign was positive in 5 patients (50.0%). Mild cerebellar signs
such as gait ataxia were found in 3 patients (30.0%). Higher mental
functions were normal in all.
6. Audiological ﬁndings
Among the 20 ears (10 patients), various degrees of hearing acuity
(from mild to profound hearing loss) were demonstrated. Pure tone
audiometric ﬁndings in them were, sensorineural (SN) hearing loss of
mild degree in 1 patient's ears (10.0%), moderate in 2 patient's ears
(20.0%), moderately severe in 2 patient's ears (20.0%), severe in 2
patient's ears (20.0%) and profound degree in 3 patient's ears (30.0%).
The results of the distortion product (DP) otoacoustic emissions
(OAE) and auditory brain stem response (ABR) were available for the
20 ears. The most signiﬁcant ﬁnding was the presence of robust OAEs
in the presence of impaired AFA (ranging frommild to profound degree
of SN hearing loss) in all. Thus, DPOAE and ABR demonstrated a neural
dysfunction.
7. Genetic ﬁndings
Screening of theSLC52A1, SLC52A2 and SLC52A3 genes in MMND
cases and family probands by Sanger sequencing of the coding and
ﬂanking intronic regions did not reveal any pathogenic mutation.
These genes were also analyzed using liquid based exome enrichment
and sequencing and were found to also be negative. The C9ORF72
expansion was analyzed and found that the GGGGCC repeats were in
the normal range of than 10.
8. Discussion
In this present report we describe a series of MMND patients and
families. All 10 patients had the classical features of MMND/MMNDV
with progressive hearing impairment associated with progressive
involvement of bulbar nuclei (7th and 9th to 10th) including severe
muscle weakness and wasting due to anterior horn cell involvement,
with pyramidal dysfunction.
It is long been debated that MMND resembles Brown–Vialetto–Van
Laere (BVVL) syndromeand theother complex childhoodmotor neuron
disease syndromes which consist of Boltshauser syndrome, Nathalie
syndrome and Fazio–Londe syndrome [24,30]. Over the last 110 years
after its initial description, only 39 cases of BVVL syndrome have been
documented worldwide [31]. In contrast we have seen more than 120
cases of MMND at a single neurological center over a 38 year period.
BVVL syndrome is distinctly a rare familial disorder with slow or rapid
progression of bilateral nerve deafness, involvement of the seventh to
twelfth cranial nerves and rarely the third, ﬁfth and sixth cranial nerves.
Lower motor neuron signs in the limbs are infrequently present and
pyramidal signs are rare [32], whereas in MMND lower and upper
motor neuron signs are seen in majority of patients and third or sixth
cranial nerve is never noted to be affected. In BVVL syndrome a female
preponderance (M:F; 1:5) has been reported while in MNND a male
preponderance or equal distribution is noted. In BVVL syndrome, more
than 50% of reported cases are familial, and also autosomal dominant
inheritance with variable penetrance and X-linked inheritance was
postulated in some families [33].
This clinico-genetic study of MMND presents the clinical phenotype
of a number of cases that have been characterized in detail. The genetic
exclusion of the three genes that have been reported to cause the
classical BVVL phenotype and the C9ORF72 which is the commonest
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distinct from these other forms of the disease. This suggests that
MMND represents a distinct form of childhood onset motor neuron
disease and does not, as previously suggested share any of the genes
associated with BVVL like disorders.
The similarity of MMND with BVVL and the other early onset child-
hood motor neuron diseases suggests that the familial form MMND is
likely to share a common or associated pathological pathway. It is also
possible that MMND could be caused by a combination of genetic and
environmental factors and of course we cannot exclude the possibility
that these diseases could be associated with an unknown expanded
repeat, as in the case of C9ORF72whichwould be very difﬁcult to identify
using Sanger or next generation techniques. MMND is familial and
sporadic and we suggest further analysis of the genetic and environmen-
tal factors to identify the causes of this disorder.
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